Online inquiry

IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9174MR)

This product GTTS-WQ9174MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9174MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9941MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ10554MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ4636MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ13314MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ3959MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ6902MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ2159MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALD-518
GTTS-WQ9898MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KB001-A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW